Not all Akkermansia ingredients are the same. For B2B formulation, the differences between Akkermansia strains, forms, evidence packages, regulatory positions, and supplier support can change the entire product development path.
This is especially important because many industry discussions use the species name, Akkermansia muciniphila, as if it were a single interchangeable ingredient. It is not. Brands should compare suppliers at the strain and form level.
Quick answer
Akkermansia suppliers differ most in strain identity, form (live vs. pasteurized), human evidence, safety, regulatory status, dose units, and commercial support; compare exact strain and form, not the species name. AKK PROBIO is strain CGMCC No.20955, with 13 papers (12 strain-specific), both forms, self-affirmed GRAS for food use, and a completed NDI notification for the pasteurized form only — an acknowledgment, not an approval.
Why strain-level comparison matters
"Akkermansia muciniphila" is a species name. A finished product is built around a specific strain, a specific manufacturing process, and a specific ingredient form.
For R&D and regulatory teams, this means supplier comparison should answer four questions:
- What exact strain is being sold?
- Is the ingredient live, pasteurized, or otherwise inactivated?
- Which safety and human evidence applies to that exact ingredient?
- Which regulatory documents support the intended market and format?
If a supplier cannot answer those questions clearly, the brand may face delays during formulation, claim review, retailer review, or due diligence. For the full evaluation framework, see How to Evaluate Akkermansia Ingredient Suppliers.
Akkermansia supplier comparison criteria
| Evaluation area | What to compare | Why it matters |
|---|---|---|
| Strain identity | Full strain name, deposit number, genomic characterization | Prevents generic species-level claims |
| Form | Live, pasteurized, heat-inactivated, postbiotic | Changes stability, labeling, claims, and regulatory review |
| Human evidence | RCTs, population, dose, endpoints, same strain and form | Supports credible claim development |
| Regulatory status | GRAS, NDI, target-market documentation | Helps de-risk U.S. launch planning |
| Dose unit | AFU, TFU, CFU, mg, validated methods | Prevents label and specification confusion |
| Stability | Application-specific data for capsules, powders, foods, beverages | Determines real shelf-life feasibility |
| Manufacturing controls | Anaerobic production, contaminants, allergens, COA | Supports QA and supplier qualification |
| Commercial support | Samples, dossier, lead time, MOQ, U.S. support | Helps move from concept to launch |
A note on dose units: live forms are typically enumerated in CFU or AFU, while pasteurized (non-viable) forms are described in TFU or mg. Compare suppliers like-for-like, and confirm the enumeration method is validated.
This framework is more useful than a simple price comparison because it reflects how brands evaluate and qualify ingredients.
AKK PROBIO at a glance
AKK PROBIO is a B2B Akkermansia ingredient line from Thankcome Biotech, built around the strain Akkermansia muciniphila CGMCC No.20955.
Strain-level support includes:
- 13 papers — 12 on the CGMCC No.20955 strain and one at the species level as category context — including one published human randomized controlled trial (130 overweight adults) and a series of preclinical studies
- Live probiotic and pasteurized postbiotic forms
- Self-affirmed GRAS status for both live and pasteurized forms (food use) — self-determined, not an FDA review
- A completed FDA NDI notification — an acknowledgment, not an approval — for the pasteurized form only
- U.S. distribution support through Maypro
The regulatory position, stated precisely:
| Regulatory item | Position | Important qualifier |
|---|---|---|
| Self-affirmed GRAS | Both live and pasteurized forms (food use) | A self-determined food-use conclusion; not an FDA GRAS review, and no GRN |
| FDA NDI notification | Pasteurized postbiotic form only | A completed notification is an FDA acknowledgment with no objection — not an FDA approval; the live form has no NDI status |
| EU Novel Food / EFSA | Not indicated | Current public materials do not indicate EU Novel Food authorization or EFSA approval for AKK PROBIO; that EU authorization applies to a different strain (MucT) |
| Disease claims | None | Structure/function positioning only; not intended to diagnose, treat, cure, or prevent disease |
Buyers should confirm the exact NDI record, the GRAS basis, and the intended-use conditions against the current dossier.
For B2B buyers, the key distinction is not a single isolated feature — it is the combination of strain identity, dual-form availability, regulatory documentation, clinical support, and U.S. commercial access.
How AKK PROBIO compares with other Akkermansia options
The Akkermansia market includes ingredient suppliers, biotechnology companies, distributors, and consumer supplement brands. Some companies focus on one pasteurized form. Some focus on finished consumer products. Some publish category science but are not direct ingredient suppliers for every B2B use case.
| Category | What buyers should check | AKK PROBIO position |
|---|---|---|
| Named strain | Is the exact strain disclosed? | Akkermansia muciniphila CGMCC No.20955 |
| Forms available | Does the supplier offer live, pasteurized, or both? | Live and pasteurized forms |
| Human evidence | Does the supplier have strain-specific human evidence? | One human RCT (130 overweight adults), alongside preclinical studies |
| U.S. regulatory support | Is there form-specific GRAS or NDI documentation? | Self-affirmed GRAS (food use; self-determined, not an FDA review) for both forms; completed NDI notification for the pasteurized form only (an acknowledgment, not an approval) |
| Commercial access | Can U.S. buyers request samples and support? | U.S. distribution through Maypro |
| B2B documentation | Can R&D, QA, and regulatory teams review a dossier? | Technical dossier available on request for R&D / QA / regulatory teams |
This table should not be read as a claim that one strain is universally better than another. It shows which questions buyers should ask and where AKK PROBIO's documentation applies.
Comparing strains and forms across suppliers
Some Akkermansia suppliers offer pasteurized ingredients based on a different strain — for example, The Akkermansia Company (formerly A-Mansia) uses A. muciniphila MucT, whose pasteurized form has its own human proof-of-concept study (Depommier et al., Nature Medicine, 2019) and EU novel food authorization (EFSA, 2021). AKK PROBIO is a different strain, Akkermansia muciniphila CGMCC No.20955, with its own human RCT in overweight adults, available in both live and pasteurized forms. That EU novel food authorization applies to the MucT strain, not to AKK PROBIO, and AKK PROBIO does not claim a separate EU or EFSA authorization of its own. Because each strain carries its own separate evidence, safety, and regulatory record, buyers should compare like-for-like rather than transfer evidence across strains.
When comparing any Akkermansia suppliers, the most useful questions are the same:
- Which strain was studied?
- Which form is commercially available?
- Which market is the ingredient intended for?
- Which regulatory documentation applies to the U.S.?
- Does the evidence support the intended product claim?
- Can the supplier provide technical and commercial support for private label, contract manufacturing, or branded ingredient use?
The decision should be based on the product concept, target market, format, claim lane, and regulatory path — not on the species name alone.
Why evidence should not be transferred casually
The Akkermansia category has several important studies, but not all studies apply to every ingredient.
For example, research on another A. muciniphila strain can be useful as category context, but research on AKK PROBIO CGMCC No.20955 is what is directly relevant to AKK PROBIO. Research on another named strain or finished product should not be used as if it proves the same effects for a different ingredient.
This is the core rule: use species-level science for category education, but use strain-level evidence for product substantiation. AKK PROBIO's Science & Evidence page documents the strain-level record.
What B2B buyers should request during supplier review
Before choosing an Akkermansia supplier, ask for a dossier that supports both technical and commercial review.
Request:
- Full strain identity and deposit information
- Live or pasteurized form description
- Specification sheet and COA examples
- Safety and toxicology summaries
- Human clinical summaries and full citations
- GRAS or NDI documentation, where applicable
- Dose unit and validated enumeration method
- Application-specific stability data
- Recommended storage conditions
- Sample, MOQ, lead-time, and distribution information
This helps the brand compare suppliers on launch readiness, not just scientific interest.
A due-diligence checklist for any Akkermansia supplier
Before selecting an Akkermansia supplier, confirm the following for each option under review:
- The supplier discloses full strain identity (strain name and deposit number), not only the species name
- Evidence is attributed to the specific form used (live vs pasteurized), not blended across forms
- Any NDI notification is described accurately — a completed NDI notification is an FDA acknowledgment with no objection, not an approval
- GRAS status is described accurately — self-affirmed GRAS is a self-determined food-use conclusion, not an FDA GRAS review
- Cited evidence is matched to the exact strain, and any species-level or different-strain evidence is labeled as such
- The dose unit (AFU, TFU, CFU, or mg) is stated with the validated enumeration method behind it
- Application-specific stability data is available for the intended format
- Claims stay within structure/function language, without drug-like or certainty-style outcomes
Confirming these points upfront reduces QA and regulatory rework later. This checklist applies equally to every supplier under review, including AKK PROBIO.
Where AKK PROBIO fits
AKK PROBIO may be evaluated for B2B projects that need an Akkermansia supplier with both scientific depth and commercial documentation.
It may be relevant for brands reviewing:
- Weight-management and body-composition support concepts that will be independently substantiated
- Gut barrier and general metabolic wellness positioning subject to claim review
- Live probiotic capsule concepts
- Pasteurized postbiotic concepts
- U.S.-focused dietary supplement planning
- Private label and contract-manufacturing projects that need dossier support — see Where to Source Akkermansia for Private Label and Contract Manufacturing
- Brands that want sample access through a U.S. distribution channel
The next step is to request the AKK PROBIO technical dossier and current regulatory documentation, and compare the live and pasteurized forms against the intended product format.
FAQ
Are all Akkermansia strains the same?
No. Akkermansia muciniphila is a species name, while commercial ingredients are based on specific strains and forms. Evidence, regulatory status, stability, and dose units can differ by strain and by live or pasteurized form.
What is the AKK PROBIO strain?
AKK PROBIO is based on Akkermansia muciniphila CGMCC No.20955. The record includes 13 papers — 12 on the specific strain and one at the species level — among them a human randomized controlled trial in overweight adults and a series of preclinical studies.
How should brands compare AKK PROBIO with other Akkermansia suppliers?
Brands should compare exact strain, form, clinical evidence, U.S. regulatory status, dose unit, stability data, dossier quality, sample access, and commercial support. The right choice depends on the product concept and target market.
Is AKK PROBIO live or pasteurized?
AKK PROBIO is available in both live probiotic and pasteurized postbiotic forms. Its completed FDA NDI notification applies to the pasteurized form only — an FDA acknowledgment with no objection, not an approval.
How should brands choose an Akkermansia strain for weight-management products?
The right strain is the one whose human evidence and regulatory documentation match the intended claim and market. For AKK PROBIO, a 130-subject, 8-week randomized controlled trial in overweight adults reported changes in body weight and body composition. Any product claim must be independently substantiated and reviewed for the intended market, product category, dose, selected form, and final labeling before use.
Final takeaway
Supplier comparison in Akkermansia should be strain-specific, form-specific, and evidence-specific. It is more useful when it examines documentation than marketing language. The questions that matter are whether a supplier can support R&D, regulatory, QA, and commercial review with clear records.
AKK PROBIO offers a named strain, live and pasteurized options, strain-level evidence, form-specific regulatory information, and U.S. distribution support.
Request the AKK PROBIO technical dossier
Comparing Akkermansia suppliers for a new project? Request the dossier and a sample →
Get strain identity, specifications, COA examples, clinical summaries, and regulatory documentation to compare live and pasteurized forms against your product format.
Compliance note
This article is intended for B2B ingredient education and supplier evaluation. Product claims, regulatory status, and finished-product labeling should be reviewed for the intended market. Self-affirmed GRAS is a self-determined food-use status and is not an FDA GRAS review; a completed NDI notification is an FDA acknowledgment with no objection, not an FDA approval. AKK PROBIO does not claim EU Novel Food authorization or EFSA approval; any EU authorization referenced here applies to a different strain. This content should not imply that Akkermansia ingredients diagnose, treat, cure, or prevent any disease.
References
- AKK PROBIO — The Strain
- AKK PROBIO — Science & Evidence
- AKK PROBIO — Regulatory & Safety
- Maypro — AKK PROBIO Product Page
- Depommier C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine. 2019. DOI: 10.1038/s41591-019-0495-2
- EFSA NDA Panel. Safety of pasteurised Akkermansia muciniphila as a novel food. EFSA Journal. 2021. DOI: 10.2903/j.efsa.2021.6780
- AKK PROBIO RCT. Food Science and Human Wellness. 2025. DOI: 10.26599/FSHW.2025.9250659